Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Solexa Inc.

Division of Illumina Inc.

Latest From Solexa Inc.

Abingworth Closes 12th Life Sciences Fund ABV VII At $315M

European biotechs are likely to be the big winner as transatlantic VC Abingworth closes its latest fund, Abingworth Ventures VII (ABV VII), at $315m, exceeding its $300m target.

Analysis Commercial

Abingworth Closes New Fund

Abingworth's new fund puts the London-based venture firm in position to continue investing heavily on both sides of the Atlantic.
Business Strategies

Next-generation Sequencing: Slowly Moving towards the $1,000 Genome

Even if most attempts to read DNA strands in real time appear stalled and the goal of true single-molecule sequencing has, with the notable exception of Helicos, for the most part given way (at least for the time being) in favor of cluster-based approaches with lower data densities, there's still plenty of opportunity for start-ups to advance the field of next-generation sequencing: with microfluidics, nanotechnology, and biochemistries to better enable direct DNA observation and analysis.
BioPharmaceutical Innovation

Illumina Buys Solexa

The $600 million Illumina is paying to acquire next-generation sequencing company Solexa says more about current market drivers and meeting Illumina's immediate need for growth than it does about the technology's future application as a means of achieving the oft-touted goal of the $1,000 genome sequence.
Business Strategies Manufacturing
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Solexa Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Illumina Inc.
  • Senior Management
  • John West, CEO
    Linda Rubinstein, VP, CFO
    Simon Bennett, Dir., Bus. Dev.
    Tony Smith, VP, CSO
  • Contact Info
  • Solexa Inc.
    Phone: (510) 670-9300
    25861 Industrial Blvd.
    Hayward, CA 94545